39 - Stability Programs and Shelf Life Determination (S19E1)

Ever grab your prescription and wonder if, maybe,
just maybe, somewhere along the line, someone
found a problem with how it was made. You know,
like before it got to you. Happens more than
you think. Yeah, that's what we're diving into
today. Those little notices the FDA, the Food
and Drug Administration, sends out when they
spot something that needs fixing. We call them
Form 483 observations. And we're looking at a
whole decade's worth, specifically in the drug
world. 10 years of, oh, oh, you might want to
take a look at this. Right. So between 2020 and
2024, what were the trends? What kept popping
up in these 483s? What are the big issues the
FDA has been flagging in drug manufacturing?
That's our deep dive today. Big question is,
what does it all tell us about how safe and effective
our medicines really are? Exactly. So to get
to the bottom of this, we've got a lot of stuff
to look at. We do, starting with those 483s themselves.
That's the core, right? Seeing what the AAA actually
found. Makes sense. But we also need the context.
So the rules, the actual regulations these companies
are supposed to be following, that's where the
Code of Federal Regulations Title 21 comes in.
It's like the Bible of drug manufacturing. So
like chapter and verse of how to make a pill?
Kind of. It's got everything. How you design
the buildings, think part 110. All the lab controls,
that's a part 211. Even down to labeling, that's
part 202. Sounds thorough. It's meant to be.
But rules are one thing. Putting them into practice
is another. So we're also looking at guides,
handbooks, best practices for things like designing
a facility, setting up audits, what a good GMP
professional actually does day to day. Getting
into the nitty gritty. Got it. Plus, we've got
some real world stories, investigations from
the past, to see how these things and to bring
it up to date, we've even got insights from regulatory
experts. Oh, like insider info? Some of it, and
even the FDA themselves, they've got all sorts
of stuff on their YouTube channels, training
sessions, conferences. It's a mix of here's what
you need to know, and this is what we're seeing
out there. So we're going deep behind the curtain
of how our meds are made. But for our listener...
Why does all this matter? Why should they care
about these 483s? Because at the end of the day,
these observations point to real challenges,
challenges the pharma industry faces in like
consistently hitting that quality bar. And that
impacts every single one of us who takes medication.
Right. It's not just paperwork. It's our health.
Exactly. So whether it's about documentation
or like how equipment is maintained, understanding
these issues helps us see why having strong quality
systems in place is so crucial. It's not just
red tape. It's about safety and effectiveness.
Gotcha. So today we're cutting through the jargon,
extracting those key insights from all this material.
What are the FDA's most common findings? What
do they mean for drug quality? And most importantly,
how can manufacturers not just fix the problems,
but actually prevent them in the first place?
That's it. And right off the bat, when you look
at those 483s, one thing is clear. The FDA is
seeing this persistent compliance challenges
thing. It's like, despite all the rules and the
efforts, these issues just keep cropping up.
That's a little worrying. So where are these
challenges popping up the most? What's catching
the FDA's eye time and time again? Well, the
analysis highlighted a few key areas. In a quality
control unit, they're supposed to be the guardians
of quality, right? But how well are they actually
fulfilling those responsibilities? That's one.
Makes sense. What else? Investigations. When
something goes wrong, how deeply are companies
digging to figure out why? Are they doing thorough
discrepancy investigations? So it's not just,
oops, fixed it. It's what does it happen? Exactly.
Then there's the paperwork. Are there written
procedures, there SOPs? Up to scratch. Complete,
accurate, easy to follow. You'd be surprised
how often that's an issue. Paperwork. Always
the paperwork. And then, of course, there's the
lapse. Are their controls tight enough? Are they
using validated methods? Got it. So basically,
are they doing everything by the book to make
sure the tests are accurate and reliable? That's
it. And last but not least, equipment maintenance.
Are they keeping things clean, calibrated, in
good working order? Right, because a rusty machine
can't make good medicine. Okay, let's unpack
one of those areas. Let's talk documentation.
Those SOPs, the standard operating procedures,
why is getting the paperwork right such a huge
deal? Imagine this. You're trying to follow a
recipe, but it's got steps missing, ingredients
scribbled out, no measurements. How do you know
you'll end up with what you're supposed to? A
cake disaster waiting to happen. Exactly. Drug
manufacturing is the same, only with way higher
stakes. And that's where regulations like 21
CFR Part 111 come in. Right, the rule book. It's
for dietary supplements, but the principles of
apply across the board. Every entry in a record
got to be clear, signed, or initialed, dated
by the person who do it. No mystery meet in the
process. So full transparency. And if you make
a mistake, can't just erase it, got to cross
it out with a single line, initial, and date
the correction, and explain why you made the
change? Creating a paper trail. A clear one.
And, like the EES Consulting Group folks pointed
out, sometimes it's good to have a second pair
of eyes, peer review, especially for critical
stuff, catches those little errors before they
become big problems. Two heads are better than
one. And the NZP Safety Hub folks, they had some...
Pretty specific advice on handwritten records,
right? It wasn't just about fixing errors. Oh,
yeah. They were all about real -time documentation.
Do it as you go. No scribbling from memory later.
And permanent ink. No fading. No erasing allowed.
Even the color can matter. Blue ink for regular
stuff, red for approvals, maybe green for changes.
All depends on the company's procedure. Whoa.
Color -coded drug making. Who knew? It's all
about clarity and organization. Oh, and those
blank spaces on forms. Not OK. Got to mark them
NR for not requi - or cross them out initial
and date. No sneaking in info later. Gotcha.
So whether it's paper or electronic you got to
maintain that integrity, that trustworthiness
of the record. Absolutely. No trampering. No
mystery edits. And speaking of electronic records,
they have their own set of challenges. PsiLife
was all over this. Controlled access. You know,
only certain people can make changes. Timestamped
entries. Audit trails that track every tweak.
You got to review those before a badge is even
released. And electronic signatures for approvals.
Makes those digital paper trays a lot more secure.
But that SEO transcript, they were a bit wary
of photocopying, especially with patient info.
Oh, yeah. Privacy is a big deal. Got to protect
that while still maintaining... good documentation.
It's a balancing act. Okay, let's switch gears.
Another area the FDA keeps flagging, lab controls.
The heart of quality, right? So what's going
wrong there? A lot hinges on the test methods.
Got to have validated methods, got to prove that
the tests actually measure what they're supposed
to reliably and consistently. We saw this in
those transcripts from seasons one and three.
Yeah, those examples of tablet testing really
stuck with me. Like the disintegration test,
making sure the pill dissolves properly in your
body, or the hardness test, making sure it's
not too brittle. Right. If those tests are off,
you could have a drug that doesn't work as intended
and you wouldn't even know it. And 21 CFR Part
111 is very clear on this. Got to have solid
documentation showing how you came up with the
specs for the final product and that you're using
the right tests to make sure those specs are
met. Sounds like a lot of pressure on those lab
folks. It's a big responsibility. And it's not
just about testing the final product. You got
to check the ingredients too, right? 21 CFR Part
111 also talks about examining the paperwork
from suppliers, making sure the raw materials
are up to snuff, and then you gotta quarantine
those materials until your own QC lab gives them
the thumbs up. Double check in from the get -go.
Exactly. And don't forget about reserve samples.
21 CFR parts 211 and 320, they both talk about
keeping a portion of each batch stored under
the right conditions, just in case you need to
go back and retest if there's a problem later
on. Smart. So it's like an insurance policy for
quality control. It is, and this all ties into
that idea of rigorous process control we talked
about earlier. From the moment you get those
raw materials to the final testing, everything's
got to be tightly controlled and documented.
And, you know, there are even more advanced approaches.
We talked about analytical quality by design,
AQBD in season seven. That's all about taking
a more scientific, proactive approach to developing
really robust test methods right from the start.
So staying ahead of the curve. OK, what about
the actual place where these drugs are made.
Equipment maintenance, the analysis flag, that
is a frequent issue. Why is that such a problem
area? Well, think about it. You're making medicine,
right? It's got to be clean, sterile, precise.
If the equipment is rusty, poorly calibrated,
or just plain dirty, you're asking for trouble.
And the FDA knows this. That's why 21 CFR Part
110 is so specific. It's all about preventing
contamination. Absolutely. Equipment and utensils,
they got to be designed right, made of the right
stuff, well maintained, and easy to clean. No
shortcuts. Right, because a dirty pill press
is not good for anyone. And you gotta keep records.
The EAS consulting group was very clear on that.
Calibration logs, maintenance logs for every
piece of critical equipment. If you can't prove
it's working correctly and being properly cared
for, you can't guarantee the quality of the drugs
you're making. It's like a car. Gotta keep up
with those maintenance checks. Exactly. And part
110 doesn't stop there. The facilities themselves,
where you store stuff, where you package the
finished product, all gotta be in good shape,
clean, sanitized. No cobwebs in the corner. Not
if you want to stay in business. And then there's
the whole issue of validation. You got to prove
that the equipment actually does what it's supposed
to do consistently and reliably. Hayther's book
on validation, it lists all sorts of equipment
that usually needs this. Autoclaves, compressed
air systems, HVAC, even the machines that fill
and label those bottles. So you're not just assuming
it works, you're testing it to make sure. Exactly.
And you got to document those design specs, operating
procedures, safety features. It's a whole process.
And Jacobs and Signore, they made a great point
in their book about GMP facility design. They
said the way you design and maintain your facility
directly affects how much those drugs cost to
make. So it's not just about quality, it's about
efficiency too. Makes sense. So a well -maintained
facility and equipment, it's not just checking
a box, it's good business all around. Right.
And then there's the issue of when things go
wrong, those discrepancy investigations. Right.
Because stuff happens. So what's the FDA looking
for when there's a problem? They want to see
that you understand your process inside and out
and that you're taking steps to control it. That's
where process validation comes in. 21 CFR Part
110. It's all about making sure manufacturing
happens under controlled conditions. You got
to monitor things like time, temperature, humidity.
Keeping everything in that sweet spot. Exactly.
So when something deviates or a batch fails,
a thorough investigation is key. You got to dig
deep, figure out why, and then take steps to
prevent it from happening again. Derivage's GMP
handbook actually talks about this. Even when
you have to rework a batch, you need a validated
process for that. So it's not just fixing it,
it's understanding why it broke in the first
place. And then fixing the process so it doesn't
break again. And the FDA has been pushing this
idea of a more proactive approach for years now.
They even had this pharmacy CGMP for the 21st
century initiative all about encouraging innovation
and risk management in manufacturing. So it's
not just about following the rules, it's about
understanding the why behind them and using that
knowledge to improve. Exactly. Okay, we've talked
about docs, labs, equipment, investigations,
but what about the people doing all this work?
Training feels like that's got to be huge. Yeah,
you can have the best equipment and procedures,
but if the people using them are trained properly,
it's a recipe for disaster. Right. And while
training deficiencies might not have been in
the top five most cited categories in those 483s,
think about it. How many of those other issues
could stem from a lack of training? Makes sense.
A poorly trained worker could mess up documentation,
misread a lab test, or operate equipment incorrectly.
Exactly. And we saw this in a couple of those
transcripts, the one on FDA requirements for
clinical investigators. It was all about making
sure everyone involved in a trial is properly
trained. And the EAS consulting group, they linked
proper training to better data review and stronger
quality systems overall. So investing in training
your staff is investing in quality. No shortcuts
there. None. Okay, let's talk about what happens
when the FDA does find problems. They issue that
form 483. What does that mean for the company?
Yeah, what are the consequences? It can be pretty
serious. That history of a CGMP medical event
investigation text, it talked about how a 483
can lead to more scrutiny, more audits, even
regulatory actions. And it's not just Big Pharma
that needs to worry. The comprehensive analysis
of FDA form 483 observations made it clear that
CDMOs, those contract manufacturers, they're
also on the hook. So no one gets a free pass?
Nope. And ultimately, the biggest impact is on
public health. If these quality issues aren't
fixed, the safety and effectiveness of the drugs
people depend on is at risk. That's the bottom
line. And it can even lead to recalls. We saw
that in a couple of those quality risk management
sources. Right. And that FDA training course
transcript, it talked about how the FDA categorizes
their findings, NII, VAI, OAI. A 483 usually
means it's a VAI or OAI, meaning the FDA thinks
action is needed. So it's not just a slap on
the wrist, it's a you need to fix this now. Exactly.
Which brings us to CAPA, corrective and preventive
action. That's how companies address these observations
and prevent new ones. So it's about learning
from your mistakes and making things better.
It is, and the FDA is big on this, the FDA regulatory
affairs text. It explained that a good CAPA system
is like the engine of improvement for a company's
quality system. Keeps things running smoothly.
Right, and it's fed by lots of data, audits,
testing results, equipment records, even customer
feedback. All of that goes into figuring out
what went wrong and how to fix it. So it's not
just reacting, it's proactively looking for ways
to improve. Exactly. And the FDA training course
transcript, it emphasized responding to each
483 observation individually, say whether you
agree or disagree, and then provide a detailed
CAPA plan with realistic timelines and ways to
check if the fixes actually worked. So it's a
detailed action plan. It is. And that CAPA for
the FDA regulated industry text, it highlighted
that how fast you got to those cafes depends
on the risk. Some of things are critical, gotta
be fixed yesterday. Others, you've got a bit
more breathing room. Makes sense. So it's a tailored
approach depending on the severity of the issue.
Right. And then there's quality risk management.
It's all about being proactive. ICH Q9, Season
3, all those quality risk management sources
talked about this. You identify potential problems
before they happen, assess the risks, and then
put controls in place to minimize those risks.
So you're staying a step ahead. Exactly. And
there are tools to help with this. FMEA, failure
mode and effects analysis. That's a big one.
You basically brainstorm all the ways something
could go wrong and then figure out how to prevent
it. So being prepared for anything. OK, let's
wrap up. What are the big takeaways from this
deep dive into a decade of FDA 483s. It's clear
that certain things are absolutely crucial in
drug manufacturing. Documentation, it's got to
be thorough, meticulous. Lab controls, stringent,
reliable. Equipment, well maintained, calibrated.
And the processes themselves got to be validated.
No room for error there. None. And training can't
emphasize that enough. Everyone involved needs
to know the rules, the procedures, inside and
out. And underpinning all of this is KYPA, that
commitment to fixing problems and continuously
improving. It's what keeps everything running
smoothly and ensures those medicines are safe
and effective. And this might seem like technical
stuff, behind -the -scenes stuff, but it affects
all of us. It does. These aren't just regulations
on a piece of paper. They're about our health,
our well -being. Exactly. So here's a final thought
for our listeners. The pharma industry is always
evolving. new technologies. How do we keep up?
How do regulators and manufacturers adapt to
ensure quality stays high and these recurring
issues are addressed? And how do we maintain
public trust in the system? It's a big question
and it's one we all need to be thinking about.
It is. And for those who want to dig deeper,
check out the FDA's website. They've got a public
database of 483s. You can see what they're finding
out there. Plus, they've got tons of resources
on GMP, those good manufacturing practices. And
the ICH, the International Council for Harmonization,
they've got some great guidelines, too. Knowledge
is power, right? It is. All right. That's our
deep dive for today. Thanks for joining us. Thanks
for having me.